

1. Originalarbeiten

1. Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM. Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA4-4 Antibodies: Association with Overall Survival? *PLoS One*. 10.1371/journal.pone.0139438 (2015).
Impact factor: 3.73
2. Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, Moch H, Curioni-Fontecedro A. A novel germline mutation of PDGFR-beta might be associated with clinical response of colorectal cancer to regorafenib. *Annals of Oncology*. 26: 246-248 (2015).
Impact factor: 6.578
3. Friemel J, Rechsteiner M, Frick L, Böhm F, Struckmann K, Egger M, Moch H, Heikenwalder M, Weber A. Intratumor heterogeneity in hepatocellular carcinoma. *Clinical Cancer Research*. 21: 1951-1961 (2015).
Impact factor: 8.193
4. Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt LP, Hejhal T, Catalano A, Busenhardt P, Gonçalves AF, Brandt S, Bode PK, Bode-Lesniewska B, Wild PJ, Frew IJ. A versatile modular vector system for rapid combinatorial mammalian genetics. *The Journal of Clinical Investigation*. 125: 1603-1619 (2015).
Impact factor: 13.765
5. Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. *Cancer Cytopathology*. 122: 48-58 (2014).
Impact factor: 3.807
6. Rechsteiner, M. P., Floros, X., Boehm, B. O., Marselli, L., Marchetti, P., Stoffel, M., Moch, H., Spinas, G. A. Automated assessment of beta-cell area and density per islet and patient using TMEM27 and BACE2 immunofluorescence staining in human pancreatic beta-cells
PLoS One. 10.1371/journal.pone.0098932 (2014)
Impact factor: 3.73
7. Rechsteiner M, Müller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz MG, Moch H, Wild PJ, Zimmermann DR, Tinguely M. Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing. *Experimental Hematology Oncology*. 10.1186/2162-3619-3-18 (2014).
Impact factor: none
8. Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ. KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation. *Journal of Pathology* (2014). doi: 10.1002/path.4390.
Impact factor: 7.585 (2013)
9. Markus P, Rechsteiner, Xenofon Floros, Bernhard O. Boehm, Lorella Marselli, Piero Marchetti, Markus Stoffel, Giatgen A. Spinas, Holger Moch. Automated assessment of β -cell mass in human pancreatic islets. *PLoSOne*. Jun 6;9(6) (2014).
Impact factor: 3.73 (2012)
10. Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. *Virchows Archive*. 463(5):623-31 (2013).
Impact factor: 2.276 (2012)
11. Zimmermann A-K, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M. Value of immunohistochemistry in the detection of BRAF (V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. *Cancer Cytopathology*. 122(1):48-58 (2013).
Impact factor: 4.434 (2012)
12. Markus Rechsteiner, Anne-Katrin Zimmermann, Peter J. Wild, Rosmarie Caduff, Adriana von Teichman, Daniel Fink, Holger Moch, Aurelia Noske. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. *Journal of Experimental Molecular Pathology*. 95(2):235-41 (2013).
Impact factor: 2.128 (2012)

13. Markus Rechsteiner, Adriana von Teichman, Jan H. Rüschoff, Niklaus Fankhauser, Bernhard Pestalozzi, Peter Schraml, Achim Weber, Peter Wild, Dieter Zimmermann, Holger Moch. KRAS, BRAF and TP53 deep-sequencing for colorectal carcinoma patient diagnostics. *Journal of Molecular Diagnostics*. 15(3):229-311 (2013).
Impact factor: 3.952 (2012)
14. Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H. The Protein-Tyrosine Phosphatase Receptor Type J is regulated by the pVHL-HIF axis in Clear Cell Renal Cell Carcinoma. *Journal of Pathology*. 229(4):525-34 (2013).
Impact factor: 7.585 (2012)
15. Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas A, Fink D, Moch H, Krek W, Frew IJ. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. *EMBO Mol Med*. 4(8):808-24 (2012).
Impact factor: 7.795 (2012)
16. Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerewinkel N. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. *Nature Communication*. 1:3:811 (2012).
Impact factor: 10.015 (2012)
17. Morra L, Rechsteiner M, Casagrande S, von Teichman A, Schraml P, Moch H, Soltermann A. Characterization of periostin isoform pattern in non-small cell lung cancer. *Lung Cancer*. 76(2):183-90 (2012).
Impact factor: 3.392 (2012)
18. Daria Esterházy, Ina Stützer, Haiyan Wang, Markus P. Rechsteiner, Jeremy Beauchamp, Heinz Döbeli, Hans Hilpert, Hugue Matile, Alexander Schmidt, Nora Lieske, Bernhard Boehm, Loretta Marselli, Ruedi Aebersold, Giatgen A. Spinass, Holger Moch, Cristiano Migliorini and Markus Stoffel. Bace2 is a β -cell enriched protease that regulates pancreatic β -cell function and mass. *Cell Metabolism*, 14(3):365-77 (2011).
Impact factor: 14.619 (2012)
19. Laura Morra, Markus Rechsteiner, Silvia Casagrande, Roger Santimaria, Glen Kristiansen, Peter Schraml, Holger Moch and Alex Soltermann. Relevance of Periostin and its Splice Variants in Renal Cancer. *American Journal of Pathology*, 179(3):1513-21 (2011).
Impact factor: 4.522 (2012)
20. Markus P. Rechsteiner, Adriana von Teichman, Anna Nowicka, Tullio Sulser, Peter Schraml, and Holger Moch. VHL gene mutations and their effects on HIF α : Identification of potential driver and passenger mutations. *Cancer Research*. 71(16): 5500-11 (2011).
Impact factor: 8.65 (2012)
21. Zauner L, Melroe GT, Sigrist JA, Rechsteiner MP, Dorner M, Arnold M, Berger C, Bernasconi M, Schaefer BW, Speck RF, Nadal D TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification. *Oncogene*, 29(32):4588-98 (2010).
Impact factor: 7.357 (2012)
22. Floros X, Fuchs T, Rechsteiner MP, Spinass G, Moch H, Buhmann JM. Graph-Based Pancreatic Islet Segmentation for Early Type 2 Diabetes Mellitus on Histopathological Tissue. *MICCAI*, Volume 5762/2009, 633-640 (2009).
Impact factor: kein (2012)
23. Rechsteiner MP, Berger C, Zauner L., Sigrist JA, Weber M, Longnecker R, Bernasconi M, Nadal D. Latent membrane protein 2B regulates susceptibility to activation of lytic Epstein-Barr virus infection. *Journal of Virology*, 82: 1739 - 1747 (2008).
Impact factor: 5.076 (2012)
24. Rechsteiner MP, Berger C, Weber M, Sigrist JA, Nadal D, Bernasconi M. Silencing of latent membrane protein 2B (LMP2B) reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells. *Journal of General Virology*, 88: 1454 – 1459 (2007).
Impact factor: 3.127 (2012)
25. Rao SP, Rechsteiner MP, Berger C, Sigrist JA, Nadal D, Bernasconi M. Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt lymphoma Akata cells. *Molecular Cancer*, 6:3 (2007).
Impact factor: 5.134 (2012)
26. Rechsteiner MP, Widmer F, Kölliker R. Expression profiling of Italian ryegrass (*Lolium multiflorum* Lam.) during infection with the bacterial wilt inducing pathogen *Xanthomonas translucens* pv. *graminis*. *Plant Breeding* 125, 43-51 (2006).
Impact factor: 1.175 (2012)

27. Farres J, Rechsteiner MP, Herold S, Frey AD, Kallio PT. Ligand binding properties of bacterial hemoglobins and flavohemoglobins.
Biochemistry, 15;44(10):4125-34 (2005).
Impact factor: 3.377 (2012)

2. Fallbeschreibungen (case reports)

3. Übersichtsarbeiten (Reviews)

28. Rechsteiner MP, Bernasconi M, Berger C, Nadal D. Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency.
Trends in Microbiology, 16 (11): 520-7 (2008).
Impact factor: 8.434 (2012)

4. Buchbeiträge

29. Rechsteiner MP. Function of Latent Membrane Protein 2B in EBV-positive Burkitt's Lymphoma.
Südwestdeutscher Verlag für Hochschulschriften, ISBN-Nr.: 978-3-8381-0660-1 (2009).
Impact factor: none (2013)